Who Owns Hikma Company?

Hikma Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Hikma Pharmaceuticals PLC?

Understanding a company's ownership is key to grasping its strategy and market impact. For a global pharmaceutical firm like Hikma, knowing its owners sheds light on its long-term goals and commitment to healthcare.

Founded in 1978, Hikma has grown into a major player in the pharmaceutical industry, now headquartered in London and listed on the FTSE 100. Its mission remains focused on making quality medicines accessible.

The Darwazah family, who founded the company, continues to hold a significant stake, influencing its strategic direction. Alongside the founding family, institutional investors and public shareholders form the broader ownership base. This mix of ownership shapes the company's governance and its approach to markets, including its presence in areas like generic medicines, which are crucial for affordability and access, as detailed in the Hikma PESTEL Analysis.

Hikma Pharmaceuticals PLC was founded in 1978 in Amman, Jordan, by Samih Darwazah. His vision was to create high-quality Arab medicines comparable to Western pharmaceuticals, driven by a commitment to community contribution. The company's early development involved strategic partnerships and licensing agreements, laying the foundation for its future growth and ownership evolution.

Founder's Vision Samih Darwazah established Hikma with the goal of producing pharmaceuticals that could compete with international standards. Early Partnerships Initial growth was fueled by joint ventures and licensing agreements, including one with a Japanese firm. Family Involvement Samih Darwazah's children, Said and Mazen Darwazah, joined the company early on, contributing to its expansion. Quality Commitment The company's dedication to quality was underscored by its Jordan manufacturing site receiving US FDA approval in 1996. Global Ambition The founding team's ambition was to build a company with a global presence and high operational standards. Founding Year Hikma Pharmaceuticals was established in 1978, marking the beginning of its journey in the pharmaceutical industry.

While specific early equity details are not publicly disclosed, the Darwazah family's entrepreneurial spirit and strategic vision were central to Hikma's initial development. This family-driven approach was instrumental in transforming a modest factory in Jordan into a significant regional pharmaceutical supplier. The company's early focus on adhering to international standards, as evidenced by its US FDA approval, set a precedent for its future growth and ownership structure, as detailed in the Brief History of Hikma.

Founders and Early Ownership

The establishment of Hikma Pharmaceuticals in 1978 by Samih Darwazah marked the beginning of a family-led enterprise focused on quality and global reach.

• Founded in Amman, Jordan, in 1978 by Samih Darwazah.
• Initial mission to create Arab medicine rivaling Western pharmaceuticals.
• Early growth supported by licensing and joint ventures.
• Family members, including Said and Mazen Darwazah, played key roles.
• First Arab pharmaceutical company to achieve US FDA approval for its manufacturing site in 1996.
• Founding vision emphasized global standards and reach.

Hikma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Hikma Pharmaceuticals PLC's ownership structure saw a significant shift with its 2005 London Stock Exchange listing, which raised US$124 million. This event provided greater financial flexibility for growth and acquisitions, fundamentally altering its corporate landscape.

The Darwazah family, through Darhold Ltd., remains the largest single shareholder in Hikma Pharmaceuticals PLC, holding 27.22% of the company's shares as of June 30, 2025. This substantial stake underscores their continued influence and commitment to the company's long-term vision. Institutional investors collectively own 59% of Hikma as of June 1, 2025, highlighting the significant role of global investment firms in the company's governance and performance. Among these, BlackRock, Inc. holds 5.49% and The Vanguard Group, Inc. holds approximately 3.54% of the common stock, with other notable institutional investors including Bank Julius Baer & Co. AG, UBS Asset Management AG, Baillie Gifford & Co., Mawer Investment Management Ltd., HSBC Global Asset Management (UK) Limited, Invesco Ltd., and Boston Partners Global Investors, Inc. These holdings reflect a blend of founding family stewardship and widespread institutional backing, shaping the company's strategic direction and aligning with the Mission, Vision & Core Values of Hikma.

Key Ownership Dynamics

Hikma's ownership structure is characterized by a strong founding family presence alongside significant institutional investment. This balance influences corporate governance and strategic decision-making.

• The Darwazah family is the largest shareholder.
• Institutional investors collectively hold a majority stake.
• Major global asset managers are among the key stakeholders.
• Past share buybacks have impacted capital structure and voting rights.

Hikma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance of Hikma Pharmaceuticals PLC is managed by a Board of Directors, featuring key figures from the founding family and executive leadership, alongside independent non-executive directors. Said Samih Darwazah serves as the Executive Chairman, with Mazen Samih Darwazah as Executive Vice Chairman and President of MENA. Riad Mishlawi is the Chief Executive Officer and a Director.

Hikma Pharmaceuticals PLC operates under a one-share-one-vote principle for its ordinary shares. As of June 30, 2024, the company had 221,886,453 ordinary shares issued that carry voting rights. It's important to note that treasury shares, such as the 12,833,233 held as of June 23, 2020, do not have voting rights, meaning the total voting power is based on shares excluding these treasury holdings. The Darwazah family, through Darhold Ltd., maintains a significant ownership stake of 27.22%, granting them substantial voting power and influence over the company's strategic decisions.

Understanding Hikma's Corporate Structure

Hikma Pharmaceuticals PLC's ownership is characterized by a substantial family stake and adherence to corporate governance codes. The company's structure ensures a balance of family influence and independent oversight.

• The Darwazah family holds a significant voting block through Darhold Ltd.
• Hikma adheres to the UK Corporate Governance Code, with noted exceptions.
• Independent directors are integral to board committees, ensuring robust oversight.
• The company's voting rights are tied to its issued ordinary shares, excluding treasury shares.
• Understanding the Growth Strategy of Hikma involves recognizing the influence of its ownership structure.

Hikma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments at Hikma Pharmaceuticals PLC have subtly shifted its ownership landscape, reflecting strategic growth and adaptation to market dynamics over the past 3-5 years. The company's robust financial performance in 2024 and positive outlook for 2025, including projected revenue growth and increased operating profit, underscore its appeal to a diverse investor base.

A significant event impacting Hikma ownership was the share buyback in June 2020, where approximately 12.8 million ordinary shares were repurchased from Boehringer Ingelheim. This transaction resulted in 12,833,233 ordinary shares being held in treasury, reducing the stake of the selling entity and consolidating the company's share capital. The current ownership structure shows a strong presence of institutional investors, with 59% of shares held by institutions as of June 1, 2025, indicating a trend towards diversified ownership in the pharmaceutical sector. While the Darwazah family retains a substantial interest, the involvement of major institutional investors like BlackRock and Vanguard highlights the broad appeal of Hikma Pharmaceuticals.

Institutional Investor Dominance

As of June 1, 2025, institutional investors hold a significant 59% stake in Hikma Pharmaceuticals. This reflects a growing trend of institutional ownership in major pharmaceutical firms.

Share Buyback Impact

The June 2020 buyback of shares from Boehringer Ingelheim reduced their stake and consolidated Hikma's share capital. This move also resulted in 5.3% of shares being held in treasury.

Strategic Growth and R&D Investment

Hikma's projected 20% increase in R&D investment for 2025 across its segments signals a commitment to medium to long-term growth. This strategy is designed to attract further investor interest and maintain competitive positioning.

Transparency and Shareholder Relations

The company's consistent release of financial reports, such as the 2024 Annual Report in March 2025, and trading updates provide crucial transparency. This regular communication aids shareholders and analysts in understanding the company's financial health and strategic direction, which is a key aspect of its Marketing Strategy of Hikma.

Hikma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔